Which has more human data?

Going by the research status on each profile (GHK-Cu: Cosmetic/topical; Copper Peptide AHK-Cu: In vitro only), the labels are not on a single scale of human testing, so this page does not rank them. Each profile's References section lists the studies, with the species and study type.

What are the half-lives?

GHK-Cu: No published PK data found. Copper Peptide AHK-Cu: Topical (not systemically relevant). Figures are as reported in the cited studies, with the species where stated.

Are they FDA-approved?

GHK-Cu: research status “Cosmetic/topical”. Slated for a PCAC review (503A bulks) before end of Feb 2027; not FDA-approved as a drug. Topical cosmetic use is not drug approval. Copper Peptide AHK-Cu: research status “In vitro only”. Not FDA-approved as a drug; sold in cosmetics. See the FDA peptide regulatory tracker for sourced compounding status.

How are they administered in the research?

GHK-Cu: Subcutaneous or topical. Copper Peptide AHK-Cu: Topical. This describes the published studies and is not a recommendation for human use.

How do their proposed mechanisms differ?

GHK-Cu: In plain terms: It is a copper-carrying peptide thought to help skin rebuild collagen, based mostly on lab and animal studies. Proposed mechanisms, from laboratory and animal studies (review, Pickart 2015): GHK acts as a complex with copper(II) and stimulates both synthesis and breakdown of collagen and glycosaminoglycans; antioxidant and anti-inflammatory effects are reported in in vitro and in vivo studies (Dou 2020). A 2026 systematic review found the evidence largely preclinical (18 of 20 studies; Mokhtar 2026). Copper Peptide AHK-Cu: In plain terms: It is a small copper-carrying peptide that helped hair follicles grow in lab experiments. Proposed mechanism, from ex vivo and cell studies (Pyo 2007): the copper(II) complex of the tripeptide Ala-His-Lys stimulated elongation of isolated human hair follicles ex vivo and proliferation of cultured dermal papilla cells, and reduced dermal papilla cell apoptosis. Tripeptide-copper complexes are described in that paper as raising VEGF production by dermal fibroblasts. These are mechanisms proposed in the cited research, at the research stage listed for each compound.

GHK-Cu vs Copper Peptide AHK-Cu: Research Comparison

Built from the GHK-Cu, Copper Peptide AHK-Cu research profiles · Profiles last updated October 1, 2026 · Reviewed by The Peptide Dispatch Editorial Team

TL;DR

This page compares GHK-Cu and Copper Peptide AHK-Cu using only their research-profile data. GHK-Cu (research stage: Cosmetic/topical; half-life: Not established in published research). It is a copper-carrying peptide thought to help skin rebuild collagen, based mostly on lab and animal studies. Copper Peptide AHK-Cu (research stage: In vitro only; half-life: Topical (not systemically relevant)). It is a small copper-carrying peptide that helped hair follicles grow in lab experiments. Educational summary, not medical advice.

Where each point comes from: Clinicalhuman trials and FDA labels Lab / animalrodent, cell and ex vivo studies Community-reporteduser experience and commonly used protocols, not from clinical studies

Educational summary. Everything below is taken from each compound's research profile and describes what was reported in the cited studies — not a promise of results, a dose recommendation, or an endorsement for human use. Not medical advice. Full disclaimer.

Side-by-side comparison

	GHK-Cu	Copper Peptide AHK-Cu
Category	Healing	Healing
Research status	Cosmetic/topical	In vitro only
Regulatory note (as of Sept 2026)	Slated for a PCAC review (503A bulks) before end of Feb 2027; not FDA-approved as a drug. Topical cosmetic use is not drug approval. Regulatory tracker →	Not FDA-approved as a drug; sold in cosmetics. Regulatory tracker →
Half-life	No published PK data found	Topical (not systemically relevant)
Administration route	Subcutaneous or topical	Topical
Dosing used in published research (not a recommendation)	Topical cosmetic formulations in humans; 0.3 or 3 mg/mL intra-articular weekly x4 in rat ACL reconstruction model; systemic wound healing in rats, mice, pigs (reviews)	10^-12 to 10^-9 M AHK-Cu in ex vivo human hair-follicle organ culture and cultured dermal papilla cells (Pyo 2007).
Community-reported protocol (not from clinical studies)	Community-reported1–3 mg, subcutaneous or topical	Community-reported1–3% in topical formulations, topical
How it works (as summarized from the cited research)	In plain terms: It is a copper-carrying peptide thought to help skin rebuild collagen, based mostly on lab and animal studies. Proposed mechanisms, from laboratory and animal studies (review, Pickart 2015): GHK acts as a complex with copper(II) and stimulates both synthesis and breakdown of collagen and glycosaminoglycans; antioxidant and anti-inflammatory effects are reported in in vitro and in vivo studies (Dou 2020). A 2026 systematic review found the evidence largely preclinical (18 of 20 studies; Mokhtar 2026).	In plain terms: It is a small copper-carrying peptide that helped hair follicles grow in lab experiments. Proposed mechanism, from ex vivo and cell studies (Pyo 2007): the copper(II) complex of the tripeptide Ala-His-Lys stimulated elongation of isolated human hair follicles ex vivo and proliferation of cultured dermal papilla cells, and reduced dermal papilla cell apoptosis. Tripeptide-copper complexes are described in that paper as raising VEGF production by dermal fibroblasts.
Effects reported in research (study subjects as stated)	Lab / animalIn laboratory and animal studies (review): proposed to modulate skin-regeneration pathways (Pickart 2015) Lab / animalAccelerated wound healing in rats, mice, pigs and dogs (reviews) Lab / animalIn a systematic review of 20 studies (18 preclinical, 2 RCTs): regenerative skin effects evaluated in aesthetic medicine (Mokhtar 2026) Lab / animalHair growth reported in preclinical/cosmetic studies; no controlled human trials found	Lab / animalStimulated hair-follicle elongation ex vivo (Pyo 2007); no human clinical trial. Lab / animalDermal papilla cell activation Lab / animalVEGF elevation by tripeptide-copper reported in dermal fibroblasts (background in Pyo 2007), not shown in dermal papilla cells Lab / animalIn cell-culture studies: collagen synthesis support Lab / animalIn cell-culture studies: skin rejuvenation
Potential side effects	Skin irritation (topical) Injection-site reactions Human safety data for injection are lacking	No published human safety data found Possible local irritation (unstudied)
Profile description	Copper tripeptide complex naturally found in plasma. Declines with age and plays roles in collagen synthesis and antioxidant activity; reviews report accelerated wound healing in rats, mice, pigs and dogs.	AHK-Cu is a copper-binding tripeptide (Ala-His-Lys-Cu) related to GHK-Cu. It stimulated hair-follicle elongation ex vivo (Pyo 2007); no human clinical trial.
References cited on the profile	4	1

Key differences in the published research

Research status: GHK-Cu — Cosmetic/topical; Copper Peptide AHK-Cu — In vitro only.
Category: the same on every profile (Healing).
Reported half-life: GHK-Cu — No published PK data found; Copper Peptide AHK-Cu — Topical (not systemically relevant).
Administration route in the literature: GHK-Cu — Subcutaneous or topical; Copper Peptide AHK-Cu — Topical.
Evidence cited: GHK-Cu’s profile lists 4 references; Copper Peptide AHK-Cu’s profile lists 1 reference.

Regulatory status

GHK-Cu: On the FDA peptide regulatory tracker: Removed from Category 2; not yet reviewed by PCAC. Details →
Copper Peptide AHK-Cu: Not FDA-approved as a drug; sold in cosmetics. Details →

For the sourced, dated status of every peptide in FDA's 2026 compounding actions, see the FDA peptide regulatory tracker.

Frequently Asked Questions

Which has more human data?: Going by the research status on each profile (GHK-Cu: Cosmetic/topical; Copper Peptide AHK-Cu: In vitro only), the labels are not on a single scale of human testing, so this page does not rank them. Each profile's References section lists the studies, with the species and study type.
What are the half-lives?: GHK-Cu: No published PK data found. Copper Peptide AHK-Cu: Topical (not systemically relevant). Figures are as reported in the cited studies, with the species where stated.
Are they FDA-approved?: GHK-Cu: research status “Cosmetic/topical”. Slated for a PCAC review (503A bulks) before end of Feb 2027; not FDA-approved as a drug. Topical cosmetic use is not drug approval. Copper Peptide AHK-Cu: research status “In vitro only”. Not FDA-approved as a drug; sold in cosmetics. See the FDA peptide regulatory tracker for sourced compounding status.
How are they administered in the research?: GHK-Cu: Subcutaneous or topical. Copper Peptide AHK-Cu: Topical. This describes the published studies and is not a recommendation for human use.
How do their proposed mechanisms differ?: GHK-Cu: In plain terms: It is a copper-carrying peptide thought to help skin rebuild collagen, based mostly on lab and animal studies. Proposed mechanisms, from laboratory and animal studies (review, Pickart 2015): GHK acts as a complex with copper(II) and stimulates both synthesis and breakdown of collagen and glycosaminoglycans; antioxidant and anti-inflammatory effects are reported in in vitro and in vivo studies (Dou 2020). A 2026 systematic review found the evidence largely preclinical (18 of 20 studies; Mokhtar 2026). Copper Peptide AHK-Cu: In plain terms: It is a small copper-carrying peptide that helped hair follicles grow in lab experiments. Proposed mechanism, from ex vivo and cell studies (Pyo 2007): the copper(II) complex of the tripeptide Ala-His-Lys stimulated elongation of isolated human hair follicles ex vivo and proliferation of cultured dermal papilla cells, and reduced dermal papilla cell apoptosis. Tripeptide-copper complexes are described in that paper as raising VEGF production by dermal fibroblasts. These are mechanisms proposed in the cited research, at the research stage listed for each compound.

References

GHK-Cu

The Regenerative Potential of GHK-Cu in Aesthetic Medicine
Mokhtar J, Mohamad B, Haddad J, Said A, Menon A, Kreutz-Rodrigues L et al. Aesthetic surgery journal. 2026. PMID: 42619529.
Study type: Systematic review, 20 studies (18 preclinical, 2 RCTs).
DOI: 10.1093/asj/sjag169 · PubMed
GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration
Pickart L, Vasquez-Soltero JM, Margolina A. BioMed research international. 2015. PMID: 26236730.
Study type: Review.
DOI: 10.1155/2015/648108 · PubMed
The potential of GHK as an anti-aging peptide
Dou Y, Lee A, Zhu L, Morton J, Ladiges W. Aging pathobiology and therapeutics. 2020. PMID: 35083444.
Study type: Review.
DOI: 10.31491/apt.2020.03.014 · PubMed
Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction
Fu SC, Cheuk YC, Chiu WY, Yung SH, Rolf CG, Chan KM. Journal of orthopaedic research : official publication of the Orthopaedic Research Society. 2015. PMID: 25731775.
Study type: Rat model, n=72.
DOI: 10.1002/jor.22831 · PubMed

Copper Peptide AHK-Cu

The effect of tripeptide-copper complex on human hair growth in vitro
Pyo HK, Yoo HG, Won CH, Lee SH, Kang YJ, Eun HC et al. Archives of pharmacal research. 2007. PMID: 17703734.
Study type: Ex vivo human hair follicles + cultured DPCs.
DOI: 10.1007/BF02978833 · PubMed

Read the full profiles

From Our Affiliated Clinic

Prefer physician oversight for peptide therapy?

1836 Wellness — operated by the same company as The Peptide Dispatch — offers physician-supervised protocols, 76-marker blood panels, and bio-age scoring.

Visit 1836 Wellness →

Disclosure: The Peptide Dispatch and 1836 Wellness are commonly owned by 1836 Wellness LLC. We may benefit financially if you become a client of 1836 Wellness. Learn more.

Educational content — not medical advice. Effects described are drawn from cited research in study subjects.

← Compare Peptides Peptide Database Regulatory Tracker Home